Understand adverse-event terminology, sample size and follow-up before interpreting a reassuring safety headline.
An adverse event is an unwanted medical occurrence recorded during or after exposure to a product. It does not by itself prove that the product caused it. FDA distinguishes this from an adverse drug reaction, for which a causal connection is attributed. This distinction is essential in both directions: every reported event should not automatically be blamed on the substance, and an uncertain causal relationship is not a reason to ignore a possible signal. Good safety assessment collects enough detail to investigate, rather than demanding immediate certainty.
Seriousness is a regulatory classification based on outcomes such as death, a life-threatening event, hospitalisation or significant disability, and on certain other medically important events. Severity describes intensity. A symptom can feel severe without meeting a seriousness criterion, while an event described in mild-sounding language can still have a serious outcome. Read the paper's definitions before comparing its totals. The number of all adverse events, the number of serious events and the number attributed to treatment are different summaries and should be labelled separately.
Preparing the full guide…
The extended sections are available during your one-minute preview and with free email registration.
- Zero observed events does not mean zero risk
- Duration is another part of the denominator
- Study selection affects what can be learned
- A comparison group helps interpret background events
- Postmarketing reports detect signals, not simple rates
- Use precise safety language
Sources & further reading
Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.
- FDA — Understanding postmarket safety surveillance programmes and public data
- FDA — What is a serious adverse event?
- FDA — Step 5: Postmarket drug safety monitoring
- FDA — Required postmarketing studies: limits of clinical trial safety data